Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

about

Novel therapeutic modalities and drug delivery - erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations.

P2860

Q50224629-99A69B34-B349-4508-9CA5-786972D4ED7D

P2860

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

Item

http://www.wikidata.org/entity/Q53134314

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@en

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@nl

type

Item

label

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@en

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@nl

prefLabel

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@en

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@nl

P1476

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

@en

P2093

Jaiprakash N Sangshetti

http://www.w3.org/2001/XMLSchema#string

Mufassir Mushtaque Momin

http://www.w3.org/2001/XMLSchema#string

Rana Zainuddin

http://www.w3.org/2001/XMLSchema#string

Zahid Zaheer

http://www.w3.org/2001/XMLSchema#string

P2860

Polymersome-based drug-delivery strategies for cancer therapeutics

Erlotinib in previously treated non-small-cell lung cancer

MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

Interaction of nanoparticles with cells.

Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians

Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies.

Factors affecting the clearance and biodistribution of polymeric nanoparticles.

Strategies in the design of nanoparticles for therapeutic applications.

Cyclodextrin-based nanosponges: A critical review.

Nanoparticulation improves bioavailability of Erlotinib.

P304

1-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/21691401.2017.1360324

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28758795

http://www.w3.org/2001/XMLSchema#string

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

about

P2860

P2860

Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P577

P698